A Natural History Study of Canavan Disease



Status:Recruiting
Conditions:Metabolic
Therapuetic Areas:Pharmacology / Toxicology
Healthy:No
Age Range:Any - 99
Updated:6/22/2018
Start Date:May 2016
End Date:May 2019
Contact:Camille Corre, BS
Email:ccorre@partners.org
Phone:617-724-6374

Use our guide to learn which trials are right for you!

A Natural History Study of Canavan Disease: MGH Site

The purpose of this study is to learn more about the natural history of Canavan disease

For this study, families of subjects will fill out a Canavan Patient Survey which asks
questions about disease development, symptoms and progression. Patients will be seen in Dr.
Eichler's Leukodystrophy clinic for standard of care appointments. These appointments will be
scheduled every 6 months.

The investigators will also collect MRI images and reports that have already been done or
which will be done during participation in the study on a clinical basis.

GLOBAL UNIQUE IDENTIFIERS (GUID):

A patient Global Unique Identifier (GUID) will be used as the identifier for individuals
participating in the study in NeuroBANK™. The GUID is an 11-character string that is
generated using encryption technology and algorithms licensed by the NCRI from the National
Institutes of Health (NIH).

The GUID is generated on a secure website that utilizes 128-bit Secure Socket Layer (SSL). Of
note, this website is not linked to NeuroBANK™. The GUID is generated using an irreversible
encryption algorithm - it accepts twelve identifying data elements, (e.g. last name at birth,
first name at birth, gender at birth, day, month and year of birth, city and country of
birth, etc.), and produces a unique random-generated character string, or GUID. No
identifying information is stored in the system; it is simply used to generate the GUID. If
the same information is entered again, the same GUID will be returned.

The GUID is entered into NeuroBANK™ when the patient is being created in the system. As the
same patient may participate in multiple studies, NeuroBANK™ will also allow capturing a
study-specific ID for the patient. For more information about NeuroBANK™ or the GUID, please
go to: www.neurobank.org.

Data Management:

The NCRI Data Management Team is trained and knowledgeable regarding confidentiality and
integrity of data. They will be responsible for all aspects of data procedures. Alex Sherman
is the ALD Connect network strategist and member of the NEALS ALS consortium. He is the
director of Strategic Development and Systems of NCRI, serves on the Executive Committee of
the ALS Research Group, and is one of the leaders of the NEALS ALS Consortium.

Data Quality Checks, Logic Checks and Queries:

The Data Manager (DM) at the Neurological Clinical Research Institute (NCRI) at the
Massachusetts General Hospital will conduct monthly Data Quality Checks, Logic Checks, and
internal data quality audits. Data field queries will be resolved in an established workflow
according to the Standard Operating Procedures (SOPs). The queries may be created either at
the point of entry during the data entry process, manually by the NCRI DM, or as the result
of executing monthly Logic Checks.

Study-Specific Database Backup and Maintenance:

The NCRI personnel will be responsible for the database backups that will be conducted daily.
Simultaneously, a separate copy of the backup in the encrypted compressed format will be
maintained and saved by the System Analysts. The backups will be saved on a separate computer
partition in a password-protected compressed format and also will be burnt into DVD medium
and stored in a secure location.

Inclusion Criteria:

- The patient must have a confirmed diagnosis of Canavan Disease as defined by elevated
NAA levels, decreased ASPA activity, or mutations in the ASPA gene.

Exclusion Criteria:

- The PI will assess whether it is in the best interest of the patient to exclude them
from the study for their own comfort and well being. In cases where the PI deems it
appropriate, severely affected patients will be excluded
We found this trial at
3
sites
New York, New York 10016
Principal Investigator: Heather Lau, MD
Phone: 212-263-6628
?
mi
from
New York, NY
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Florian Eichler, MD
Phone: 617-724-6374
?
mi
from
Boston, MA
Click here to add this to my saved trials
Hamburg, 20246
Principal Investigator: Annette Bley, MD
Phone: +49 40 7410 56391
?
mi
from
Hamburg,
Click here to add this to my saved trials